Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis.
暂无分享,去创建一个
H A Lehr | S J Schnitt | A. Gown | S. Schnitt | H. Lehr | H. Yaziji | A M Gown | T. Jacobs | H Yaziji | T W Jacobs | H. Lehr | Hans-Anton Lehr
[1] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[2] L. Holmberg,et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Skoog,et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. , 1995, European journal of cancer.
[4] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[5] J. Brisson,et al. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[6] F. Waldman,et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.
[7] David A. Mankoff,et al. Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[8] D. Persons,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[9] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.
[10] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[12] D. Marx,et al. Overexpression of the Oncogene c‐erbB-2 (HER2/neu) and Response to Chemotherapy in Patients with Ovarian Cancer , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[13] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Kay,et al. C-erbB-2 immunostaining: problems with interpretation. , 1994, Journal of clinical pathology.
[15] D A Berry,et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.
[16] R. Weinberg,et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.
[17] A. Gown,et al. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. , 1999, Human pathology.
[18] B Fisher,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.
[19] P. Ravdin,et al. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.
[20] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[21] W. Gullick,et al. OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.
[22] J. Iglehart,et al. c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[23] M. Fernö,et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.
[24] R Akita,et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.
[25] W. Wells,et al. The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[26] B Angus,et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.
[27] B. Nakata,et al. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.
[28] J. Winstanley,et al. Cytoplasmic staining of c‐erbB‐2 is not associated with the presence of detectable c‐erbB‐2 mRNA in breast cancer specimens , 1998, International Journal of Cancer.
[29] M. Trudeau,et al. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[30] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[31] W. McGuire,et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. , 1992, Journal of the National Cancer Institute.
[32] D. Altman,et al. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.
[33] W. McGuire,et al. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. , 1992, Anticancer research.
[34] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Slamon,et al. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. , 1999, Seminars in oncology.
[36] I. Busmanis,et al. Analysis Of Cerbb2 Expression Using A Panel Of 6 Commercially Available Antibodies , 1994, Pathology.
[37] B. Têtu,et al. Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.
[38] A. Gown,et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[42] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] D. Slamon,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.
[44] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[45] B. Samuels,et al. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] Allen M. Gown,et al. Complete Chromogen Separation and Analysis in Double Immunohistochemical Stains Using Photoshop-based Image Analysis , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.